Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose

Horng Yih Ou, Yi Ching Yang, Hung Tsung Wu, Jin Shang Wu, Feng Hwa Lu, Chih Jen Chang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Context: Fetuin-A, a liver-derived glycoprotein that impairs insulin signaling, is associated with nonalcoholic fatty liver disease (NAFLD), diabetes, and the risk of cardiovascular diseases. Both prediabetes and NAFLD are associated with increased cardiovascular risk, and their concurrence significantly impairs hepatic and adipose tissue insulin sensitivity. Objective: Our objective was to investigate the relationship between serum fetuin-A levels and prediabetes in subjects with or without NAFLD. Design: This was a cross-sectional case-control study. Patients: A total of 510 age- and sex-matched subjects with normal glucose tolerance (NGT), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) with or without NAFLD were recruited. Each subject was assessed by abdominal ultrasound to diagnose NAFLD. Main Outcome Measures: Serum fetuin-A concentrations were compared between groups. The association with clinico-metabolic parameters was examined. Results: The presence of NAFLD significantly increases fetuin-A levels in subjects with NGT and prediabetes. As compared with NGT, IGT, but not IFG, significantly increases fetuin-A levels in subjects with or without NAFLD. Serum fetuin-A concentrations were positively related to postload 2-h glucose, body mass index, triglyceride, and homeostasis model assessment of insulin resistance but negatively associated with age, high-density lipoprotein cholesterol, and adiponectin. In multiple regression analysis, age, IGT vs. NGT, and IGT with NAFLD vs. NGT were independently associated with fetuin-A levels after adjustment for cardiovascular risk factors and adiponectin. Conclusions: IGT with or without NAFLD was independently associated with fetuin-A levels after adjustment for cardiometabolic risk factors. The elevated fetuin-A levels could have a clinical implication in the increased cardiovascular risk and insulin resistance associated with NAFLD and IGT.

Original languageEnglish
Pages (from-to)4717-4723
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume97
Issue number12
DOIs
Publication statusPublished - Dec 1 2012
Externally publishedYes

Fingerprint

alpha-2-HS-Glycoprotein
Glucose Intolerance
Liver
Fasting
Glucose
Prediabetic State
Insulin Resistance
Adiponectin
Insulin
Serum
Non-alcoholic Fatty Liver Disease
HDL Cholesterol
Adipose Tissue
Case-Control Studies
Glycoproteins
Triglycerides
Body Mass Index
Homeostasis
Cardiovascular Diseases

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. / Ou, Horng Yih; Yang, Yi Ching; Wu, Hung Tsung; Wu, Jin Shang; Lu, Feng Hwa; Chang, Chih Jen.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 97, No. 12, 01.12.2012, p. 4717-4723.

Research output: Contribution to journalArticle

@article{8dfb2281e5e347e1b64d89827ab073cb,
title = "Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose",
abstract = "Context: Fetuin-A, a liver-derived glycoprotein that impairs insulin signaling, is associated with nonalcoholic fatty liver disease (NAFLD), diabetes, and the risk of cardiovascular diseases. Both prediabetes and NAFLD are associated with increased cardiovascular risk, and their concurrence significantly impairs hepatic and adipose tissue insulin sensitivity. Objective: Our objective was to investigate the relationship between serum fetuin-A levels and prediabetes in subjects with or without NAFLD. Design: This was a cross-sectional case-control study. Patients: A total of 510 age- and sex-matched subjects with normal glucose tolerance (NGT), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) with or without NAFLD were recruited. Each subject was assessed by abdominal ultrasound to diagnose NAFLD. Main Outcome Measures: Serum fetuin-A concentrations were compared between groups. The association with clinico-metabolic parameters was examined. Results: The presence of NAFLD significantly increases fetuin-A levels in subjects with NGT and prediabetes. As compared with NGT, IGT, but not IFG, significantly increases fetuin-A levels in subjects with or without NAFLD. Serum fetuin-A concentrations were positively related to postload 2-h glucose, body mass index, triglyceride, and homeostasis model assessment of insulin resistance but negatively associated with age, high-density lipoprotein cholesterol, and adiponectin. In multiple regression analysis, age, IGT vs. NGT, and IGT with NAFLD vs. NGT were independently associated with fetuin-A levels after adjustment for cardiovascular risk factors and adiponectin. Conclusions: IGT with or without NAFLD was independently associated with fetuin-A levels after adjustment for cardiometabolic risk factors. The elevated fetuin-A levels could have a clinical implication in the increased cardiovascular risk and insulin resistance associated with NAFLD and IGT.",
author = "Ou, {Horng Yih} and Yang, {Yi Ching} and Wu, {Hung Tsung} and Wu, {Jin Shang} and Lu, {Feng Hwa} and Chang, {Chih Jen}",
year = "2012",
month = "12",
day = "1",
doi = "10.1210/jc.2012-2414",
language = "English",
volume = "97",
pages = "4717--4723",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose

AU - Ou, Horng Yih

AU - Yang, Yi Ching

AU - Wu, Hung Tsung

AU - Wu, Jin Shang

AU - Lu, Feng Hwa

AU - Chang, Chih Jen

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Context: Fetuin-A, a liver-derived glycoprotein that impairs insulin signaling, is associated with nonalcoholic fatty liver disease (NAFLD), diabetes, and the risk of cardiovascular diseases. Both prediabetes and NAFLD are associated with increased cardiovascular risk, and their concurrence significantly impairs hepatic and adipose tissue insulin sensitivity. Objective: Our objective was to investigate the relationship between serum fetuin-A levels and prediabetes in subjects with or without NAFLD. Design: This was a cross-sectional case-control study. Patients: A total of 510 age- and sex-matched subjects with normal glucose tolerance (NGT), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) with or without NAFLD were recruited. Each subject was assessed by abdominal ultrasound to diagnose NAFLD. Main Outcome Measures: Serum fetuin-A concentrations were compared between groups. The association with clinico-metabolic parameters was examined. Results: The presence of NAFLD significantly increases fetuin-A levels in subjects with NGT and prediabetes. As compared with NGT, IGT, but not IFG, significantly increases fetuin-A levels in subjects with or without NAFLD. Serum fetuin-A concentrations were positively related to postload 2-h glucose, body mass index, triglyceride, and homeostasis model assessment of insulin resistance but negatively associated with age, high-density lipoprotein cholesterol, and adiponectin. In multiple regression analysis, age, IGT vs. NGT, and IGT with NAFLD vs. NGT were independently associated with fetuin-A levels after adjustment for cardiovascular risk factors and adiponectin. Conclusions: IGT with or without NAFLD was independently associated with fetuin-A levels after adjustment for cardiometabolic risk factors. The elevated fetuin-A levels could have a clinical implication in the increased cardiovascular risk and insulin resistance associated with NAFLD and IGT.

AB - Context: Fetuin-A, a liver-derived glycoprotein that impairs insulin signaling, is associated with nonalcoholic fatty liver disease (NAFLD), diabetes, and the risk of cardiovascular diseases. Both prediabetes and NAFLD are associated with increased cardiovascular risk, and their concurrence significantly impairs hepatic and adipose tissue insulin sensitivity. Objective: Our objective was to investigate the relationship between serum fetuin-A levels and prediabetes in subjects with or without NAFLD. Design: This was a cross-sectional case-control study. Patients: A total of 510 age- and sex-matched subjects with normal glucose tolerance (NGT), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) with or without NAFLD were recruited. Each subject was assessed by abdominal ultrasound to diagnose NAFLD. Main Outcome Measures: Serum fetuin-A concentrations were compared between groups. The association with clinico-metabolic parameters was examined. Results: The presence of NAFLD significantly increases fetuin-A levels in subjects with NGT and prediabetes. As compared with NGT, IGT, but not IFG, significantly increases fetuin-A levels in subjects with or without NAFLD. Serum fetuin-A concentrations were positively related to postload 2-h glucose, body mass index, triglyceride, and homeostasis model assessment of insulin resistance but negatively associated with age, high-density lipoprotein cholesterol, and adiponectin. In multiple regression analysis, age, IGT vs. NGT, and IGT with NAFLD vs. NGT were independently associated with fetuin-A levels after adjustment for cardiovascular risk factors and adiponectin. Conclusions: IGT with or without NAFLD was independently associated with fetuin-A levels after adjustment for cardiometabolic risk factors. The elevated fetuin-A levels could have a clinical implication in the increased cardiovascular risk and insulin resistance associated with NAFLD and IGT.

UR - http://www.scopus.com/inward/record.url?scp=84870736698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870736698&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-2414

DO - 10.1210/jc.2012-2414

M3 - Article

C2 - 23066121

AN - SCOPUS:84870736698

VL - 97

SP - 4717

EP - 4723

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -